PROFILE OF ANTIBIOTIC RESISTANCE AND USAGE PATTERN IN ICU OF PRIVATE HOSPITAL IN BANDUNG, INDONESIA
Objective: To evaluate the resistance and usage patterns of antibiotics in the ICU of the private hospital in Bandung Indonesia.
Methods: A cross sectional retrospective study in the period from July to December 2012 at a private hospital in Bandung Indonesia which conducted microbial identification and antibiotic sensitivity testing using Kirby Bauer method.
Results: There were 132 patients were cultured positive which sputum was the most common specimen (86.36%, n=114). Pneumonia was the most frequent diagnosis (34.3%). Thirteen bacteria obtained were Escherichia coli (31.58%) as the highest isolates, followed by Pseudomonas Spp. (20.18%) and Acinetobacter baumanii (10.53%). Beta lactam group was found as the most frequent antibiotic use especially meropenem. The highest rate of microbial resistance was to Ampicillin including E. coli, K. pneumoniae, Stenotrophomonas Sp., Enterobacter Spp., Serratia Sp. Those isolates were 100% resistant to ampicillinandA. baumannii isolate were 83.3% resistant to Ampicillin.
Conclusion: The resistance rate and the usage of high beta-lactam antibiotics in the ICU required good management in making programs for infection control, surveillance of resistant bacteria, monitoring the use of antibiotics in hospitals, making a sustainable new guidelines for the usage of antibiotics and prophylaxis, and monitoring the usage of antibiotics in hospitals.
2. Mohammadi-mehr M, Feizabadi M. Antimicrobial resistance pattern of Gram-negative bacilli isolated from patients at ICUs of army horpital in Iran. Iranian J Microbiol 2011;3(1):26-30.
3. Carlet J, Ben AA, Tabah A, Willems V, Philippart F, Chafine A, et al. Multidrug resistant infections in the ICU: mechanisms, prevention and treatment. In 25 Years of Progress and Innovation in Intensive Care Medicine. Edited by Kuhlen R, Moreno R, Ranieri VM, Rhodes A. Berlin, Germany: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2007. p. 199-211.
4. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the Intensice Care Uit. Ann Intensive Caree 2011;1:47.
5. Anupurba S, Sen MR. Antimicrobial resistance profil of bacterial isolates from intensive care unit: changing trends. J Commun Dis 2005;37(1):58-65.
6. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility: Sixteenth informational supplement. Wayne, PA: CLSI; 2006. p. M100-S16.
7. Tennant I, Harding H, Nelson M, Roye-Green K. Microbial isolates from patients in an intensive care unit, and associated risk factors. West Indian Med J 2005;54(4):225-31.
8. Meybeck A, Jean-Damien R, GuilÃ¨ne B, Mathieu E, Guillaume C, Roman M, et al. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study. BMC Infect Dis 2008;8:67.
9. World Health Organization. Pneumonia; 2013. http://www.who.int/mediacentre/factsheets/fs331/en/
10. Davis KA. Ventilator-associated pneumonia: a review. J Intensive Care Med 2006;21(4):211-26.
11. GMO Compass. Glossary. http://www.gmo-compass.org/eng/glossary/. 2013. access by 11 July 2013.
12. Mohr JF. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008;47(1):41-51.